After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 4, 2025, the Compensation ...

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

The primary analysis of KATHERINE, a phase 3, open-label trial, showed that the risk of invasive breast cancer or death was 50% lower with adjuvant trastuzumab emtansine (T-DM1) than with ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

Twenty-four-year-old Caitlyn Micholson is fighting cancer and for a chance to access lifesaving alternative treatment that is ...

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

Trastuzumab emtansine (T-DM1) significantly improves long-term survival in high-risk HER2-positive breast cancer patients post-surgery, reducing the risk of death or invasive disease by 46% ...

The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...